Medical Device Industry News

  • J&J Ordered to Pay $1 Billion Over Metal-on-Metal Hips

    The company says it plans to immediately appeal the verdict, which ordered the company to pay over $1 billion in compensatory and punitive damages to six plaintiffs who were implanted with defective hip devices. Kristopher Sturgis

  • Teleflex Shelling Out $1 Billion to Buy Vascular Solutions

     The deal caps an eventful year for Vascular Solutions and its CEO, Howard Root.Maureen Kingsley

  • Medtronic Adds First U.S. Cath, EP Labs to Management Portfolio

    The medtech giant will help manage the labs at the University Hospitals Cleveland Medical Center. Nancy CrottiMedtronic will manage catheterization and electrophysiology laboratories for a Cleveland hospital, expanding a three-year-old foreign initiative to the United States.

  • EU Approves Abbott-St. Jude Merger

    There were conditions attached to the approval, though. Nancy Crotti The European Commission has approved the $25 billion merger of Abbott Labs and St. Jude Medical, contingent on Abbott selling two cardiovascular devices.

  • Zimmer Biomet Launches Personalized Shoulder Implant

    The Comprehensive Vault Reconstruction System is meant to meet an unmet need for shoulder specialists.Chris Newmarker

  • Theranos Accused of Voiding Test Reports

    Walgreens claims that the blood-testing firm voided or corrected 31,000 test reports.Nancy CrottiWalgreens claims that Theranos “voided and/or corrected tens of thousands of tests” performed on Walgreens customers without telling the drugstore chain it was doing so, according to a partially redacted legal filing.

  • Artificial Pancreas Race Intensifies

    Sponsored by the University of Virginia and funded by NIH, a new clinical trial combines advanced technologies from three medtech companies.Maureen Kingsley

  • Abbott CEO Buys $15 Million in Stock

    Abbott Labs CEO Miles White is obviously positive about the company’s situation amid pending purchases of St. Jude Medical and Alere.Chris NewmarkerCount Abbott Laboratories CEO Miles White among those who see the company’s stock as a good buy.

  • Boston Sci's Watchman Takes Heat

    U.S. FDA and CMS approvals were based on incomplete information, according to a prominent cardiologist.Nancy CrottiA prominent cardiologist is calling for colleagues to stop using Boston Scientific’s Watchman device, which is meant to prevent strokes in patients with atrial fibrillation.

  • BD Wants to Boost Insulin Infusion Tech

    The company's focus is on a specific technology that would help enable a true artificial pancreas for type 1 diabetes patients. Maureen Kingsley